Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Dalia Kamel"'
Publikováno v:
Current Oncology, Vol 28, Iss 3, Pp 2190-2198 (2021)
Background: In 2012, the American Society for Clinical Oncology (ASCO) identified five key opportunities in oncology to improve patient care, recommending against imaging tests for the staging of patients with early breast cancer (EBC) at low risk fo
Externí odkaz:
https://doaj.org/article/645236b21a5a446a918cdfc2950b3e9c
Publikováno v:
Assiut Journal of Agricultural Sciences. 54:48-62
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96e2fbd6768af4319df976ddc61a9942
https://doi.org/10.21608/ajas.2023.191073.1227
https://doi.org/10.21608/ajas.2023.191073.1227
Publikováno v:
Current Oncology
Volume 28
Issue 3
Pages 203-2198
Current Oncology, Vol 28, Iss 203, Pp 2190-2198 (2021)
Volume 28
Issue 3
Pages 203-2198
Current Oncology, Vol 28, Iss 203, Pp 2190-2198 (2021)
Background: In 2012, the American Society for Clinical Oncology (ASCO) identified five key opportunities in oncology to improve patient care, recommending against imaging tests for the staging of patients with early breast cancer (EBC) at low risk fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb00cb8cc282980a90c6890063f95318
Autor:
Jim Biagi, Adrian Baranchuk, Usama Boles, H. Abdollah, Christopher S. Simpson, Fariha Sadiq Ali, Andres Enriquez, Dalia Kamel, Wilma M. Hopman, Kevin A. Michael, Damian P. Redfearn, D. Campbell
Publikováno v:
JACC: Clinical Electrophysiology. 3:50-56
Objectives This study evaluated the incidence of ventricular arrhythmia and implantable cardioverter-defibrillator (ICD) therapies in patients with a diagnosis of cancer. Background Cardiac disease and cancer are prevalent conditions and share common
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90961a01789a85a23885e6d4eb49ca59
https://doi.org/10.1016/j.jacep.2016.03.001
https://doi.org/10.1016/j.jacep.2016.03.001
Autor:
Lisa Vandermeer, Andrew Robinson, Anil A. Joy, Osama Souied, Dean Fergusson, Mark Clemons, Sheryl McDiarmid, John Hilton, Sasha Mazzarello, Brian Hutton, Nathalie LeVasseur, A. Brianne Bota, Risa Shorr, Mathew McInnes, Carol Stober, Dalia Kamel
Publikováno v:
Breast cancer research and treatment. 171(3)
Systemic chemotherapy can be administered either through a peripheral vein (IV), or centrally through peripherally inserted central catheter (PICC), totally implanted vascular access devices (PORTs) or tunnelled cuffed catheters. Despite the widespre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9d80d99a2426b58b38ac2fbe9b67918
https://pubmed.ncbi.nlm.nih.gov/29974358
https://pubmed.ncbi.nlm.nih.gov/29974358
Publikováno v:
Current Drug Targets. 19
Background PARP inhibitors appear to offer a promising role in the accompaniment of many of the cytotoxic agents used in the present day to combat cancer proliferation in BRCA ½ deficient tumors. Current species of PARP inhibitors have yet to demons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::767de2a69766395354f5d5b50239ab30
https://doi.org/10.2174/1389450118666170711151518
https://doi.org/10.2174/1389450118666170711151518
Publikováno v:
World Sustainable Development Outlook
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10be4f70c029e9f6b0ecf0e748251a27
https://doi.org/10.47556/b.outlook2017.15.21
https://doi.org/10.47556/b.outlook2017.15.21
Publikováno v:
Cancer Treatment Communications. 4:128-130
Small cell lung carcinoma (SCLC) accounts for 15–20% of all lung cancers and is the most aggressive lung-cancer subtype. Even with treatment median overall survival is short, in the range of 9–12 months. Tobacco smoking is the main risk factor wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::144a6ec77bef61e22a8c4333d97e5b77
https://doi.org/10.1016/j.ctrc.2015.08.005
https://doi.org/10.1016/j.ctrc.2015.08.005
Publikováno v:
Current Cancer Therapy Reviews. 9:8-23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560bc7f095b91efc015e88ab75e409fd
https://doi.org/10.2174/1573394711309010002
https://doi.org/10.2174/1573394711309010002
Autor:
Ricardo J. Fernandes, Dominick Bossé, Michael Ong, Osama Souied, Dalia Kamel, Dong Vo, Haoran Li, Vikaash Kumar
Publikováno v:
Journal of Clinical Oncology. 35:e16500-e16500
e16500 Background: Patients with metastatic castrate resistant prostate cancer (mCRPC) often develop bone metastases, resulting in a risk of symptomatic skeletal events (SSE). Bone-targeted agent (BTA) has been integrated into the overall treatment s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::692e10a9e953dba6c4635d1d42ee2c65
https://doi.org/10.1200/jco.2017.35.15_suppl.e16500
https://doi.org/10.1200/jco.2017.35.15_suppl.e16500